Cas9-based ribonucleoproteins engineered via directed evolution and encapsulated in optimized lipid nanoparticles improve genome-editing efficacies in the livers and lungs of mice.
The CONNECT2-EDO51 phase 2 trial looks at PGN-EDO51, an investigational therapy for Duchenne muscular dystrophy (DMD), and is still ongoing in the United Kingdom. The most-read gene therapy ...
For this, ACSS2 and ACLY were deleted from naïve gp33-specific transgenic TCR P14+ CD8+ 5 T cells using single-guide (sg) RNAs with Cas9 ribonucleoproteins (RNPs) (CRISPR-Cas9/RNP) via ...
References [1]Hassfeld W, Steiner G, Graninger W, et al. Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis.Br J Rheumatol 1993;32(3):199-203. [2]Caporali R, Bugatti S, ...
This important study addresses how 3' splice site choice is modulated by the conserved spliceosome-associated protein Fyv6. The authors provide compelling evidence that Fyv6 functions to enable ...
Zhejiang Key Laboratory of Smart Biomaterials and Center for Bionanoengineering, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou Zhejiang 310058, China ...